Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 6/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21513805 | 0.94 | PARP1 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL21513915 | 0.91 | PARP1 (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13547 | 0.87 | PARP1 (0.37) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14850303 | 0.86 | BTK (0.34) | — | |
| SCHEMBL14850297 | 0.86 | PDCD1LG2 (0.35) | CD274 | |
| SCHEMBL14850266 | 0.85 | EP300 (0.40) | PARP1VSIRHRH4HRH3PDCD1 | |
| SCHEMBL14850298 | 0.85 | PDCD1LG2 (0.35) | CD274 | |
| SCHEMBL21513920 | 0.85 | PARP1 (0.38) | PARP1VSIRHRH4HRH3PDCD1 | |
| SCHEMBL21513916 | 0.84 | PARP1 (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14850307 | 0.84 | CD274 (0.39) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322668-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-10-24 | — | — | US | disclosed |
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9221827-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140163049-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MELINTA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | HDAC3 2555/4885HDAC4 2407/4885HDAC1 2713/4885 |
| US-20190322668-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | HDAC3 2555/4885HDAC4 2407/4885HDAC1 2713/4885 |
| US-20140163049-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | HDAC3 2555/4885HDAC4 2407/4885HDAC1 2713/4885 |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | HDAC3 2555/4885HDAC4 2407/4885HDAC1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.